|
111 |
Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
Enthalten in Bone marrow transplantation Bd. 55, 30.10.2019, Nr. 5, date:5.2020: 843-850
|
|
|
|
112 |
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma
Enthalten in Blood cancer journal Bd. 14, 13.2.2024, Nr. 1, date:12.2024: 1-4
|
|
|
|
113 |
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
Enthalten in Blood cancer journal Bd. 8, 15.1.2018, Nr. 1, date:1.2018: 1-5
|
|
|
|
114 |
The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers
Enthalten in Bone marrow transplantation Bd. 57, 27.9.2021, Nr. 1, date:1.2022: 11-13
|
|
|
|
115 |
Therapy of posttransplant poor graft function with eltrombopag
Enthalten in Bone marrow transplantation Bd. 56, 22.6.2020, Nr. 1, date:1.2021: 4-6
|
|
|
|
116 |
To Mars and beyond. Space exploration and space medicine in Leukemia
Enthalten in Leukemia Bd. 38, 22.5.2024, Nr. 9, date:9.2024: 1869
|
|
|
|
117 |
Transplant indications, guidelines and recommendations: Caveat Emptor
Enthalten in Bone marrow transplantation Bd. 57, 28.10.2021, Nr. 2, date:2.2022: 149-151
|
|
|
|
118 |
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?
Enthalten in Blood cancer journal Bd. 14, 23.1.2024, Nr. 1, date:12.2024: 1-3
|
|
|
|
119 |
VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis
Enthalten in TH open Bd. 05, 2021, Nr. 04: e513-e520
|
|
|
|
120 |
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
Enthalten in Experimental hematology & oncology Bd. 10, 19.3.2021, Nr. 1, date:12.2021: 1-5
|
|
Administration
